دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Long-awaited action on rare diseases
doi : 10.1016/S2665-9913(22)00072-8
Volume 4, Issue 4, April 2022, Page e229
Strategy lessons from a new clinical trial in psoriatic arthritis
doi : 10.1016/S2665-9913(22)00039-X
Volume 4, Issue 4, April 2022, Pages e231-e232
Women with gout and COVID-19—an unfortunate combination?
doi : 10.1016/S2665-9913(22)00026-1
Volume 4, Issue 4, April 2022, Pages e233-e234
COVID-19 vaccine perceptions and uptake: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey
Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease
doi : 10.1016/S2665-9913(21)00417-3
Volume 4, Issue 4, April 2022, Pages e241-e243
Systemic sclerosis and COVID-19 vaccines: a SPIN Cohort study
doi : 10.1016/S2665-9913(21)00416-1
Volume 4, Issue 4, April 2022, Pages e243-e246
Cellular responses to SARS-CoV-2 vaccination after B-cell depletion: conflicting results from studies
doi : 10.1016/S2665-9913(22)00032-7
Volume 4, Issue 4, April 2022, Page e247
Cellular responses to SARS-CoV-2 vaccination after B-cell depletion: conflicting results from studies – Authors' reply
doi : 10.1016/S2665-9913(22)00035-2
Volume 4, Issue 4, April 2022, Pages e247-e248
Correction to Lancet Rheumatol 2022; 4: e262–73
doi : 10.1016/S2665-9913(22)00070-4
Volume 4, Issue 4, April 2022, Page e249
Titilola (Lola) Falasinnu: looking out for the overlooked
doi : 10.1016/S2665-9913(22)00071-6
Volume 4, Issue 4, April 2022, Page e251
Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 study
doi : 10.1016/S2665-9913(22)00008-X
Volume 4, Issue 4, April 2022, Pages e262-e273
Gout and the risk of COVID-19 diagnosis and death in the UK Biobank: a population-based study
doi : 10.1016/S2665-9913(21)00401-X
Volume 4, Issue 4, April 2022, Pages e274-e281
